← ANALYST RATINGS · TIPRANKS
Compugen (CGEN): analyst forecast and price target
Analyst consensus
Strong Buy4 Buy0 Hold0 Sell
Ratings of 4 analysts in the last 3 months12-month forecast
Based on 4 price targets given in the last 3 months, the average target is $4.50, the highest $6.00, the lowest $4.00. The average is +129.6% from the last price of $1.96.
Analyst ratings 8
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $2.50 → $2.00−20.0% | Buy | +2.0% | Reiterated | 15.10.26on TipRanks Oct 14 23:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $2.50 → $2.00−20.0% | Hold | +2.0% | Downgrade | 15.10.26on TipRanks Oct 14 23:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $2.50 → $2.00−20.0% | Hold | +2.0% | Downgrade | 15.10.26on TipRanks Oct 14 23:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $2.50 → $2.00−20.0% | Hold | +2.0% | Downgrade | 15.10.26on TipRanks Oct 14 23:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $2.50 → $2.00−20.0% | Buy | +2.0% | Reiterated | 15.10.26on TipRanks Oct 14 23:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $2.50 → $2.00−20.0% | Hold | +2.0% | Downgrade | 15.10.26on TipRanks Oct 14 23:06 | — | |
| Swayampakula Ramakanth★★★★★★★★★★#445 · hits 47% · avg +21.2% | H.C. Wainwright | $4.00 | Buy | +104.1% | Reiterated | 12.10.26on TipRanks 06:50 | −2.8%next day −4.3% | ↗ |
| Chad Messer★★★★★★★★★★#9258 · hits 37% · avg −0.2% | Lake Street | $6.00 | Buy | +206.1% | Reiterated | 06.10.26on TipRanks 08:50 | −4.4%next day −2.9% · 5 days −10.7% | ↗ |
| Leland Gershell★★★★★★★★★★#2332 · hits 40% · avg +6.2% | Oppenheimer | $4.00 | Buy | +104.1% | Reiterated | 06.10.26on TipRanks 08:30 | −4.4%next day −2.9% · 5 days −10.7% | ↗ |
| Stephen Willey★★★★★★★★★★#1608 · hits 45% · avg +8.1% | Stifel Nicolaus | $4.00 | Buy | +104.1% | Reiterated | 06.10.26on TipRanks 08:30 | −4.4%next day −2.9% · 5 days −10.7% | ↗ |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $3.00 → $2.50−16.7% | Buy | +27.6% | Reiterated | 05.10.26on TipRanks Oct 4 23:05 | — | |
| Swayampakula Ramakanth★★★★★★★★★★#445 · hits 47% · avg +21.2% | H.C. Wainwright | $4.00 | Buy | +104.1% | Reiterated | 01.10.26on TipRanks 10:40 | −1.9%next day −2.0% · 5 days −10.7% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $2.50 | Buy | +27.6% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $3.00 → $2.50−16.7% | Buy | +27.6% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $2.50 | Buy | +27.6% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $2.50 | Buy | +27.6% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $3.00 | Buy | +53.1% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $2.50 | Buy | +27.6% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| Chad Messer★★★★★★★★★★#9258 · hits 37% · avg −0.2% | Lake Street | $5.00 → $6.00+20.0% | Buy | +206.1% | Reiterated | 21.07.26on TipRanks Jul 26 21:09 | +5.6%next day −2.7% · 5 days −8.2% | ↗ |
| Daina Graybosch★★★★★★★★★★#12254 · hits 39% · avg −7.8% | Leerink Partners | $13.00 → $5.00−61.5% | Buy | +155.1% | Reiterated | 21.05.26on TipRanks 06:15 | −3.7%next day +6.9% · 5 days −1.1% | ↗ |
| Asthika Goonewardene★★★★★★★★★★#5130 · hits 41% · avg +2.0% | Truist Financial | $4.00 | Buy | +104.1% | Reiterated | 03.03.26on TipRanks 07:35 | −10.2%next day +6.3% · 5 days +12.5% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Compugen
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $5.00 at a price of $2.38 (+110.1%); now: $4.50 at $1.96 (+129.6%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 4 | 8 |
| Buy | 1 | 1 | 1 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 16.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.08 (from $-0.10 to $-0.06). Last quarter: $-0.07.
Sales
Next quarter’s sales estimate — $1M (from $0M to $3M). Last quarter: $3M.
Best top-analyst consensus in the sector · Healthcare
About Compugen
- CEO: Eran Ophir
- Employees: 75
- Azrieli Center, Holon, TA, 5885849, IL
- cgen.com
Compugen Ltd., an Israeli-based company established in 1993 and headquartered in Holon, is a clinical-stage enterprise focused on the discovery, development, and commercialization of therapeutic and product candidates. Its operations extend across Israel, the United States, and Europe. The company’s core activities center around its immuno-oncology pipeline, which includes several investigational treatments: COM701, an anti-PVRIG antibody currently undergoing Phase I clinical studies for solid tumors. COM902, a therapeutic antibody designed to target TIGIT, which is also in Phase I clinical trials as a monotherapy for advanced malignancies. Bapotulimab, an antibody targeting ILDR2, presently in Phase I clinical development for solid tumor indications. AZD2936, an innovative bispecific antibody targeting both TIGIT and PD-1, advancing through Phase I/II clinical studies for patients with advanced or metastatic non-small cell lung cancer. Additionally, Compugen maintains earlier-stage immuno-oncology programs, with a particular emphasis on myeloid targets. To further its research and development, Compugen actively fosters strategic alliances. It has a collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics that modulate immune checkpoint regulators. Another key partnership is with Bristol-Myers Squibb, aimed at evaluating the safety and tolerability of COM701 when administered alongside Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor, Opdivo, in patients with advanced solid tumors. The company also collaborates with Johns Hopkins School of Medicine to investigate novel T cell and myeloid checkpoint targets, and has a distinct research collaboration with Johns Hopkins University specifically dedicated to myeloid science. Furthermore, Compugen holds a licensing agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products.
Data from the stock’s TipRanks forecast page, read 30 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗